ES
IMNM icon

Enavate Sciences’s Immunome IMNM Stock Holding History

Enavate Sciences’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$79M Sell
3,613,799
-1,154,784
-24% -$25.7M 22.48% 2
2025
Q4 		$102M Hold
4,768,583
– – 20.21% 2
2025
Q3 		$55.8M Hold
4,768,583
– – 17.05% 3
2025
Q2 		$44.3M Hold
4,768,583
– – 25.12% 1
2025
Q1 		$32.1M Buy
4,768,583
+1,290,322
+37% +$12.4M 24.18% 1
2024
Q4 		$36.9M Buy
+3,478,261
New +$42M 26.53% 2

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Enavate Sciences's IMNM Position: Q1 2026 in Review

Enavate Sciences reduced its Immunome (IMNM) stake by 24% in Q1 2026, selling an estimated $25.7M and leaving 3,613,799 shares worth $79M. The position accounts for 22.48% of the portfolio, ranked #2.

Enavate Sciences first reported a position in IMNM in Q4 2024 and has held it in 6 quarters since. The position peaked at $102M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Enavate Sciences held 3,613,799 shares of Immunome worth $79M as of Q1 2026.
  • Enavate Sciences sold 1,154,784 Immunome shares in Q1 2026, an estimated $25.7M.
  • Immunome made up 22.48% of Enavate Sciences's portfolio in Q1 2026, its #2 holding.
  • Enavate Sciences first reported a position in Immunome in Q4 2024 and has held it in 6 quarters since.
  • Enavate Sciences's Immunome position peaked at $102M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Enavate Sciences's 13F filing for Q1 2026, filed 15 May 2026.